DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.
Introduction
Immune dysfunction and inflammation have been well described in patients with schizophrenia (1, 2) . Previous research has attempted to identify specific inflammatory markers in relation to schizophrenia. For example, both Naudin et al. (3) and Lin et al. (4) found that, compared with healthy controls, patients with chronic schizophrenia had significantly higher serum levels of tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6). Several studies have suggested that the regulation of inflammatory and immunological processes may be related to the manifestation of symptoms and treatment response in schizophrenia. Our group previously reported that higher blood levels of C-reactive protein (CRP) or white blood cell count (WBC) were associated with a worse psychopathology profile in patients with schizophrenia (5, 6) . Others found that higher baseline levels of cerebrospinal fluid proinflammatory cytokine interleukin-2 (IL-2) were associated with worsening psychotic symptoms during haloperidol withdrawal (7) , while lower baseline serum levels of IL-2 were associated with greater improvement in clinical symptoms in schizophrenia patients treated with haloperidol or risperidone (8) . Researchers have also examined the potential benefit of anti-inflammatory agents in treating schizophrenia (9) . For example, celecoxib, a selective cyclooxygenase-2 (COX-2) anti-inflammatory agent, when added to risperidone in patients with an acute exacerbation of schizophrenia, significantly reduced psychopathology as measured by the PANSS total score (10) . Another study found that aspirin given as adjuvant therapy to regular antipsychotic treatment reduced the symptoms of schizophrenia (11) .
Patients with schizophrenia suffer from cognitive deficits especially in the domains of attention, verbal memory, and executive function (12) . An accumulating body of evidence now suggests that the severity of cognitive impairments is highly correlated with the real-life functioning in patients with schizophrenia (13) . Studies have suggested that inflammation may play an important role in the development of cognitive deficits in patients with schizophrenia (14) . Therefore, it is of great interest to explore the potential cognitive benefit of those agents with anti-inflammatory property in this patient population.
Telmisartan, an angiotensin II type one receptor blocker (ARB), is approved for the treatment of hypertension alone or in combination with other antihypertensive agents. Proinflammatory properties of angiotensin II as well as anti-inflammatory effects of are well established (15) (16) (17) . For example, animal studies have demonstrated that peripherally administered ARBs can prevent or reverse the inflammatory process associated with brain ischemia and stroke (18, 19) . In addition, telmisartan has been found to increase serum concentrations of adiponectin and reduce concentrations of high-sensitivity CRP (hsCRP) (20, 21) ; both of these effects are associated with protection from diabetes and atherosclerosis.
The discovery of angiotensin II receptors in the brain confirmed the existence of a brain angiotensin II system, which responds to angiotensin II generated in and transported into the brain (22) . In rats, following peripheral administration, telmisartan can penetrate the blood-brain barrier in a doseand time-dependent manner to inhibit centrally mediated effects of angiotensin II (23) . Animal studies with peripherally administered ARBs have suggested that angiotensin II is involved in the modulation of cerebral blood flow, brain development, neuronal migration, processing of sensory information, cognition, and regulation of emotional response (24) .
Aims of the study
We conducted a 12-week, randomized, doubleblind, placebo-controlled trial of telmisartan 80 mg/day as an adjunctive therapy in clozapineor olanzapine-treated patients with schizophrenia. The effects of adjunctive telmisartan treatment on body weight and metabolism, the primary outcomes of the study, were reported separately (under review). The aims of this study were to: i) Examine the effects of telmisartan on psychopathology and cognition after 12-week telmisartan treatment. ii) Examine the role of telmisartan's anti-inflammatory property in possible changes in clinical symptoms.
Methods

Participants
Adult out-patients with schizophrenia or schizoaffective disorder were recruited from an urban community-based general mental health clinic in Boston, Massachusetts. Psychiatric diagnosis was determined using the Structured Clinical Interview for DSM-IV (SCID) (25) This is a computer-generated timed test. Subjects are asked to respond as quickly as possible by pressing a key whenever two stimuli in a row are identical.
Follow-up assessment
Subjects met with the research team every 2 weeks. Each visit included the assessment of vital signs and side-effects. Study medication was dispensed during each visit. Subjects were asked to return their bottle of medication during each follow-up visit; the quantity of extra study medication in the bottle was recorded to assess adherence. At week 12, the clinical rating scales and cognitive tests were repeated.
Study medication
After screening, subjects were randomized to either telmisartan or placebo in a double-blind fashion based on a permuted block design with block size of six. Subjects took one tablet per day (40 mg telmisartan or placebo) for the first 2 weeks, and then took two tablets per day (80 mg telmisartan or placebo) for the next 10 weeks. Clinically, the usual starting dose is 40 mg once per day, and the maintenance dose is between 40 and 80 mg once per day for hypertension treatment.
Assays for inflammatory markers
Fasting blood samples for inflammatory markers including high-sensitivity C-reactive protein (hsCRP) and IL-6 were obtained at baseline and week 12. Laboratory assays were performed by the MGH GCRC Core Lab. Plasma levels of IL-6 were measured by a commercially available enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). Serum levels of hsCRP were measured via a high-sensitivity latexenhanced immunonephelometric assay on a BN II analyzer (Dade Behring, Newark, Del).
Statistical analysis
Statistical analysis was performed using SPSS (version 24.0, IBM Corp, Armonk, NY, USA). Descriptive statistics were performed to summarize demographic and clinical characteristics of the study sample. Group comparisons were performed using the independent t test for continuous variables, and the Fisher exact test or Chi-square test for categorical variables. Analysis of covariance (ANCOVA) was used to compare change scores from baseline to week 12 between the two treatment groups controlling for baseline scores and potential confounding variables. Partial correlation analysis was used to examine the relationship between variables of interest controlling for potential confounding variables. For all analyses, a P value less than 0.05 (two-tailed) was used for statistical significance. As the purpose of this proof of concept, pilot trial was more explanatory (i.e., identifying the effect of treatment) rather than pragmatic (i.e., identifying the utility of treatment for clinical practice), the statistical analysis was primarily focused on those participants who completed the study (completers), followed by ITT analysis with last observation carried forward (LOCF).
Results
Sixty-six subjects were screened. Among those, 62 were enrolled and 54 were randomized (26 in the telmisartan group, 28 in the placebo group). Forty-three patients completed the study (22 in the telmisartan group, 21 in the placebo group) and were included in the final data analysis (Fig. 1 ). There were no significant differences between the two groups in age, gender, race, marital status, diagnosis (schizophrenia or schizoaffective disorder), clozapine, or olanzapine treatment (P > 0.300). The telmisartan group tended to have more tobacco users than the placebo group (P = 0.091), lower education level (P = 0.149), and earlier age of illness onset (P = 0.142) ( Table 1) .
Psychopathology and cognition outcome measures
ANCOVA controlling for baseline value, tobacco use, education level, and age of illness onset showed a significantly greater decrease from baseline in the PANSS total score at week 12 in the telmisartan group compared with the control group (P = 0.038, Cohen's d = 0.57). However, there were no significant differences between the two groups in week 12 changes on PANSS subscale scores ( Investigator terminated N = 4 1 -due to non-compliance with study meds 1 -due to mild hyperkalemia 2 -due to low blood pressure Table 2 ).
Inflammatory markers
ANCOVA controlling for baseline value, tobacco use, education level, and age of illness onset showed that the telmisartan group had a significant decrease from baseline in plasma levels of IL-6 at week 12 compared with the control group (À1.49 AE 4.07 pg/ml vs. 0.71 AE 2.49 pg/ml, P = 0.019, d = 0.65) (mean AE SD). However, there were no significant difference between the two groups in week 12 change in serum levels of hsCRP (À0.49 AE 3.42 mg/l vs. À0.35 AE 2.67 mg/l, P = 0.866, d = 0.05). Partial correlation analysis found no significant relationships between the change in plasma levels of IL-6 and changes in PANSS total or subscale scores, SANS total score, QLS total score, or any cognitive measures (P > 0.100).
Side-effect assessment
There were no serious adverse events during the study. For all randomized subjects (N = 54), the side-effects reported in more than 5% of the subjects taking telmisartan were diarrhea, fatigue/ tiredness, dizziness/faintness, sore throat, nasal congestion, lightheadedness, and chest pain (Table 3 ). There were no significant differences between the two groups for listed side-effects except dizziness/faintness (23% in the telmisartan group vs. 4% in the control group, P = 0.047). Three subjects in the telmisartan group and none in the placebo group discontinued from the study because of a significant decrease in systolic, diastolic, or orthostatic blood pressure. The total percentages may not equal to 100% because of rounding. Week 12 change equals week 12 value minus baseline value; P values were based on ANCOVA comparing between group differences in week 12 changes controlling for baseline values, age of illness onset, education, and tobacco use. PANSS, the Positive and Negative Syndrome Scale; SANS, the Scale for Assessment of Negative Symptoms; QLS, the Heinrichs-Carpenter Quality of Life Scale; CPT, the Continuous Performance Test; HVLT, the Hopkins Verbal Learning Test.
The ITT analysis with LOCF
The analysis was repeated in the ITT population with LOCF. There were no significant differences between the two groups in demographic or general clinical characteristics (P > 0.200). ANCOVA controlling for baseline value showed a significantly greater decrease from baseline in the PANSS total score at week 12 in the telmisartan group compared with the control group (À3.7 AE 8.5 vs. 0.7 AE 8.1, P = 0.041, Cohen's d = 0.53). However, there were no significant differences between the two groups in week 12 changes on PANSS subscale scores (P > 0.200). In addition, there were no significant differences between the two groups in week 12 changes on QLS total score, or any cognitive measures (CPT d prime, hits rate, reaction time of hits, false-alarm rate, HVLT-immediate recall and delayed recall, verbal fluency, and Trails A and B) (P > 0.200). Further, there were no significant differences between the two groups in week 12 changes in serum levels of IL-6 or hsCRP (P > 0.200).
Discussion
We believe that this study represents the first double-blind, placebo-controlled clinical trial to examine the impact of adjunctive telmisartan therapy on psychopathology and cognitive function in patients with schizophrenia receiving olanzapine or clozapine. The 12-week study showed that telmisartan treatment had a beneficial effect on psychopathology as reflected by a significant decrease in PANSS total score. About two-thirds of the study participants were taking clozapine, which suggests that the majority of subjects in the study did not respond well to other antipsychotic agents. The suggested benefit of telmisartan to improve schizophrenia symptoms in a group of relatively treatment refractory patients is encouraging. Both animal and human studies have shown that ARBs ameliorate inflammatory conditions and reduce oxidative stress (31) . Our study showed that 12-week telmisartan treatment significantly decreased plasma levels of IL-6. This finding is consistent with the report based on a meta-analysis of randomized controlled trials of telmisartan therapy in the general population (32) . ARBs, telmisartan in particular, penetrate the brain parenchyma when administered systemically (33) . Telmisartan may improve schizophrenia symptoms by its antiinflammatory effect on the brain even though our study failed to show a significant relationship between the week 12 change in IL-6 and the week 12 changes in psychopathology measures.
A recent animal study reported that telmisartan attenuates cognitive impairment caused by chronic stress in rats (34) . Studies have also reported that ARBs protect against cognitive deterioration in patients with mild cognitive impairment (35) and may delay the progression of Alzheimer's disease (36) . It has been proposed that telmisartan may exert its cognitive benefit via upregulation of brain-derived neurotrophic factor (BDNF) and inhibition of neuro-inflammation and oxidativenitrosative stress (37) . Our study failed to demonstrate cognitive benefit of 12-week adjunctive telmisartan therapy in olanzapine-or clozapinetreated patients with schizophrenia. Benefits mediated via neurotrophic and anti-inflammatory mechanisms may require a longer treatment duration than the 12-week period of the current trial.
In our study, more patients experienced dizziness and faintness in the telmisartan group than in the control group, which was likely related to the blood pressure lowering effect of telmisartan. As blood pressure response to telmisartan is dose related over the range 10-80 mg (38) , future studies may consider flexible dosing of telmisartan to minimize possible side-effects of dizziness and faintness.
There are several limitations in the present study. As this was an exploratory trial, no adjustments were made for multiple comparisons. The small sample size prevents meaningful subgroup analysis for those patients receiving olanzapine or clozapine monotherapy; it is unclear whether or not telmisartan may have differential effects on psychopathology and cognition for olanzapine versus clozapine-treated patients. In addition, it is unclear if the findings from this study are generalizable to those patients taking antipsychotic agents other than olanzapine or clozapine. Another limitation is the relatively short intervention (12 weeks).
Future trials with larger sample sizes and longer durations of treatment are needed to better understand the effects of adjunctive telmisartan therapy on psychopathology, cognition, and safety in patients with schizophrenia, and to identify biomarkers or subgroups of patients that might predict treatment response. Further, it will be of great interest to examine the potential benefit of telmisartan in individuals in the prodrome phase or with first-episode psychosis.
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